Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ayalew Tefferi

Showing results (31-40 of 911) with videos related to

Pageof 92
Sort By:
Cancer Journal (Sudbury, Mass.)|November 23, 2007
JAK2 mutations and clinical practice in myeloproliferative neoplasmsAyalew Tefferi
Journal of Cellular and Molecular Medicine|January 30, 2009
Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1Ayalew Tefferi
Cancer Treatment and Research|April 21, 2009
Myeloproliferative neoplasms: thrombophilic clonal stem cell diseasesAyalew Tefferi
American Journal of Hematology|August 16, 2014
Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and managementAyalew Tefferi
Blood|April 14, 2012
Overcoming "aspirin resistance" in MPNAyalew Tefferi
American Journal of Hematology|July 25, 2018
Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and managementAyalew Tefferi
Hematological Oncology|June 15, 2018
Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemiaAyalew Tefferi
Blood|January 5, 2011
How I treat myelofibrosisAyalew Tefferi
American Journal of Hematology|February 26, 2011
ASH 2010 meeting report-Top 10 clinically-oriented abstracts in myeloproliferative neoplasmsAyalew Tefferi
The New England Journal of Medicine|February 3, 2007
JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applicationsAyalew Tefferi
Pageof 92

Showing results (31-40 of 911) with videos related to

Sort By:
Pageof 92
Cancer Journal (Sudbury, Mass.)|November 23, 2007
JAK2 mutations and clinical practice in myeloproliferative neoplasmsAyalew Tefferi
Journal of Cellular and Molecular Medicine|January 30, 2009
Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1Ayalew Tefferi
Cancer Treatment and Research|April 21, 2009
Myeloproliferative neoplasms: thrombophilic clonal stem cell diseasesAyalew Tefferi
American Journal of Hematology|August 16, 2014
Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and managementAyalew Tefferi
Blood|April 14, 2012
Overcoming "aspirin resistance" in MPNAyalew Tefferi
American Journal of Hematology|July 25, 2018
Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and managementAyalew Tefferi
Hematological Oncology|June 15, 2018
Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemiaAyalew Tefferi
Blood|January 5, 2011
How I treat myelofibrosisAyalew Tefferi
American Journal of Hematology|February 26, 2011
ASH 2010 meeting report-Top 10 clinically-oriented abstracts in myeloproliferative neoplasmsAyalew Tefferi
The New England Journal of Medicine|February 3, 2007
JAK2 mutations in polycythemia vera--molecular mechanisms and clinical applicationsAyalew Tefferi
Pageof 92